PTGX
Protagonist Therapeutics, Inc
NASDAQ · Healthcare · Biotechnology · US
$134.44
+4.42%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- 29.33x
- P/E 2027E
- —
- P/E 2028E
- 61.70x
- P/S forward
- 44.98x
Trailing multiples
Trailing twelve months
- P/E TTM
- 110.37x
- PEG TTM
- —
- Price / book
- 10.34x
- Price / sales
- 30.85x
- Price / cash flow
- 66.31x
Enterprise value
- Enterprise value
- $7.9B
- EV / sales
- 28.11x
- EV / EBITDA
- 92.29x
- EV / EBIT
- 135.85x
- Market cap
- $8.7B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026